Enavate Launches With $300m To Help Drug Developers Get Over Funding Hurdles

Patient Square Is Sole Initial Investor

The firm, helmed by former life science investment banker James Boylan, views the current difficult financial market as the perfect time to offer its expertise and capital to growing companies.

Businessman jumping on chart columns
Growing companies face a chilly market, which is where Enevate hopes to step in • Source: Alamy

Health care investment firm Patient Square Capital launched a new portfolio company on 2 May called Enavate Sciences, which itself is an investor with $300m that it will use to back therapeutic and enabling technology companies in growth mode. Former life science investment banker and current Enavate CEO James Boylan said now, when many biopharmaceutical firms are running into trouble raising cash, is the right time to launch this new venture.

Boylan most recently served as president and head of investment banking at SVB Leerink, where he led the transformation of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.